ENTA - Enanta starts mid-stage trial of EDP-938 for RSV infection

• Enanta Pharmaceuticals ( NASDAQ: ENTA ) said it started a phase 2b trial of EDP-938 to treat adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including elderly and/or those with congestive heart failure, chronic obstructive pulmonary disease (COPD) or asthma.
• In the study 180 patients will be treated with 800 mg of EDP-938 or placebo for five days and evaluated for 28 days thereafter.
• "In previous clinical studies, EDP-938 significantly improved the percentage of people with undetectable RSV RNA at the end of treatment, consistent with inhibiting viral replication," said President and CEO Jay Luly.

For further details see: